Polatuzumab vedotin-containing regimens as bridge to CART: analysis from the CART-SIE study.

Gabrielli G, Casadei B, Chiappella A, Tisi MC, Galli E, Cutini I, Di Rocco A, Donzelli L, Martino M, Policastro G, Crescimanno A, Petruzzellis G, Stella F, Visco C, Krampera M, Farina M, Angelillo P, Brunello L, Bruno B, Mannina D, Novo M, Grillo G, Argnani L, Bonifazi F, Corradini P, Zinzani PL

Open source

DOI: 10.1182/bloodadvances.2025018749
Published: 2026 Jul 14
Container: Blood advances
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1182/bloodadvances.2025018749,
  title = {Polatuzumab vedotin-containing regimens as bridge to CART: analysis from the CART-SIE study.},
  author = {Gabrielli G and Casadei B and Chiappella A and Tisi MC and Galli E and Cutini I and Di Rocco A and Donzelli L and Martino M and Policastro G and Crescimanno A and Petruzzellis G and Stella F and Visco C and Krampera M and Farina M and Angelillo P and Brunello L and Bruno B and Mannina D and Novo M and Grillo G and Argnani L and Bonifazi F and Corradini P and Zinzani PL},
  year = {2026},
  journal = {Blood advances},
  doi = {10.1182/bloodadvances.2025018749},
  url = {https://doi.org/10.1182/bloodadvances.2025018749}
}

RIS

TY  - JOUR
TI  - Polatuzumab vedotin-containing regimens as bridge to CART: analysis from the CART-SIE study.
AU  - Gabrielli G
AU  - Casadei B
AU  - Chiappella A
AU  - Tisi MC
AU  - Galli E
AU  - Cutini I
AU  - Di Rocco A
AU  - Donzelli L
AU  - Martino M
AU  - Policastro G
AU  - Crescimanno A
AU  - Petruzzellis G
AU  - Stella F
AU  - Visco C
AU  - Krampera M
AU  - Farina M
AU  - Angelillo P
AU  - Brunello L
AU  - Bruno B
AU  - Mannina D
AU  - Novo M
AU  - Grillo G
AU  - Argnani L
AU  - Bonifazi F
AU  - Corradini P
AU  - Zinzani PL
PY  - 2026
JO  - Blood advances
DO  - 10.1182/bloodadvances.2025018749
UR  - https://doi.org/10.1182/bloodadvances.2025018749
ER  -

APA

G, G., B, C., A, C., MC, T., E, G., I, C., A, D. R., L, D., M, M., G, P., A, C., G, P., F, S., C, V., M, K., M, F., P, A., L, B., B, B., D, M., M, N., G, G., L, A., F, B., P, C., & PL, Z. (2026). Polatuzumab vedotin-containing regimens as bridge to CART: analysis from the CART-SIE study.. Blood advances. https://doi.org/10.1182/bloodadvances.2025018749

Source records

pubmed · retrieved 2026-09-26T12:59:31.527Z
europe-pmc · retrieved 2026-09-26T12:59:31.529Z